Agilent Registers Facility with FDA as Medical Device Establishment | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agilent said today it has registered its 80,000 square-foot manufacturing facility in Cedar Creek, Texas, with the US Food and Drug Administration as a medical device establishment.

The registration is required for manufacturing diagnostic products, which the Santa Clara, Calif.-based firm said it intends to develop.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.